drugset
Drugs / T-1301
last change Jun 2024 re-read 3 minutes ago

T-1301

Small molecule

Developed for
lymphoma
Investigated by
Taivex Therapeutics Corporation

Trials 1

today NCT05156203 · Ph 1
202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05156203 Dec 2021 → Jan 2027 expected lymphoma Taivex Therapeutics Corporation Recruiting No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2024-06-12 Taivex Therapeutics Corporation Groundbreaking Cancer Treatments T-1201 and T-1301 to be Presented at WCC-2024 taivex.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as T-1301 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05156203 ↗
Action Inhibit “T-1301 is a novel small-molecule inhibitor of multiple kinases” NCT05156203 ↗
Modality Small molecule “T-1301 is a novel small-molecule inhibitor of multiple kinases” NCT05156203 ↗
Route Oral “T-1301 will be administered orally QD or BID” NCT05156203 ↗